Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2015 pubmed 11 citations

Topical cathelicidin (LL-37) an innate immune peptide induces acute olfactory epithelium inflammation in a mouse model.

Alt. Jeremiah A JA; Qin. Xuan X; Pulsipher. Abigail A; Orb. Quinn Q; Orlandi. Richard R RR; Zhang. Jianxing J; Schults. Austin A; Jia. Wanjian W; Presson. Angela P AP; Prestwich. Glenn D GD; Oottamasathien. Siam S

Key Findings

  • Topical LL‑37 triggers dose‑dependent inflammation in mouse olfactory epithelium
  • Higher LL‑37 levels increase neutrophil activity (MPO) and mast cell infiltration
  • Fluorescent LL‑37 spreads throughout the sinonasal epithelium, showing broad tissue exposure

Practical Outcomes

  • For anyone considering intranasal LL‑37 for immune or performance benefits, this study warns that even short‑term exposure can cause significant nasal inflammation. Keep doses very low or avoid nasal application until safety is better understood, and monitor for irritation if experimenting with this peptide.

Summary

A mouse study found that putting the immune peptide LL‑37 into the nose causes strong, dose‑dependent inflammation in the smell‑sensing tissue, bringing in immune cells like neutrophils and mast cells. This suggests that using LL‑37 topically in the nasal area could irritate and damage the lining rather than help.

Abstract

Cathelicidin (LL-37) is an endogenous innate immune peptide that is elevated in patients with chronic rhinosinusitis (CRS). The role of LL-37 in olfactory epithelium (OE) inflammation remains unknown. We hypothesized that: (1) LL-37 topically delivered would elicit profound OE inflammation; and (2) LL-37 induced inflammation is associated with increased infiltration of neutrophils and mast cells. To test our hypothesis we challenged C57BL/6 mice intranasally with increasing concentrations of LL-37. At 24 hours tissues were examined histologically and scored for inflammatory cell infiltrate, edema, and secretory hyperplasia. In separate experiments, fluorescently conjugated LL-37 was instilled and tissues were examined at 0.5 and 24 hours. To test our last hypothesis, we performed tissue myeloperoxidase (MPO) assays for neutrophil activity and immunohistochemistry for tryptase to determine the mean number of mast cells per mm(2) . LL-37 caused increased inflammatory cell infiltrate, edema, and secretory cell hyperplasia of the sinonasal mucosa, with higher LL-37 concentrations yielding significantly more inflammatory changes (p < 0.01). Fluorescent LL-37 demonstrated global sinonasal epithelial binding and tissue distribution. Further, higher concentrations of LL-37 led to significantly greater MPO levels with dose-dependent increases in mast cell infiltration (p < 0.01). LL-37 has dramatic inflammatory effects in the OE mucosa that is dose-dependent. The observed inflammatory changes in the olfactory mucosa were associated with the infiltration of both neutrophils and mast cells. Our biologic model represents a new model to further investigate the role of LL-37 in OE inflammation.

Study Information

Provider

pubmed

Year

2015

Date

2015-09-08T00:00:00.000Z

DOI

10.1002/alr.21634

Citations

11

References

43